Treatment Strategies and Long-Term Outcomes in Silent Corticotroph Adenomas: A Single-Center Retrospective Study of 367 Cases

医学 促肾上腺皮质细胞 垂体腺瘤 腺瘤 单中心 回顾性队列研究 切除术 普通外科 垂体 内科学 外科 激素
作者
Wenqiang He,Shun Yao,Yifei Yu,Zhengyuan Chen,Qilin Zhang,Nidan Qiao,Ming Shen,Xuefei Shou,Zengyi Ma,Yongfei Wang
出处
期刊:Neurosurgery [Lippincott Williams & Wilkins]
卷期号:96 (3): 611-621 被引量:6
标识
DOI:10.1227/neu.0000000000003142
摘要

BACKGROUND AND OBJECTIVES: Silent corticotroph adenoma (SCA) is a high-risk pituitary neuroendocrine tumor (PitNET) which exhibits more aggressive behavior than other nonfunctioning PitNETs. Some SCAs are observed to recur after total resection (TR). We aim to discuss the long-term outcomes after endoscopic endonasal surgery for SCAs and explore optimal treatment after operation. METHODS: Clinical data and intraoperative videos from 367 SCAs who underwent endoscopic endonasal surgery were retrospectively collected. Patients were categorized into TR and subtotal resection (STR) groups according to 3-month postoperative MRIs. Based on close-up intraoperative observation of the relationship between tumor and pituitary gland, diaphragm, and medial wall cavernous sinus, patients in the TR group were further subdivided into gross total resection (GTR) and near total resection (NTR) groups. Patients in the STR group were subdivided as STR followed by observation (STR + ob) and STR followed by adjuvant stereotactic radiosurgery (SRS) (STR + SRS). Kaplan-Meier analysis was used to compare the event-free survival among these subgroups. RESULTS: Headache (27.5%) and vision loss (55.3%) were the most common presenting symptoms. Cavernous sinus (CS) invasion was confirmed intraoperatively in 167 (45.5%) patients. After operation, 175 (47.7%), 83 (22.6%), 32 (8.7%), and 77 (21%) patients were divided into GTR, NTR, STR + ob, and STR + SRS groups, respectively. The mean follow-up time was 40.9 ± 25.8 months. There were 0, 17 (20.5%), 9 (28.1%), and 4 (5.2%) patients noted to have PitNET recurrence or progression in GTR, NTR, STR + ob, and STR + SRS groups, respectively. Event-free survival distribution in the NTR group was similar to that in the STR + ob group ( P = .696), which was significantly lower than that in the STR + SRS group ( P = .008). Adrenocorticotropic hormone (ACTH)-negative SCAs have lower preoperative ACTH levels and were more likely to invade CS than ACTH-positive SCAs. CONCLUSION: CS invasion was commonly seen in SCAs, often precluding GTR. Radical surgery and close follow-up were proposed. Early postoperative adjuvant SRS for remnant tumor should be considered.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2应助暮冬十二采纳,获得10
刚刚
guok完成签到,获得积分10
1秒前
2秒前
小何发布了新的文献求助10
2秒前
斯文败类应助凝心采纳,获得10
2秒前
酷波er应助cJLin采纳,获得10
2秒前
Kyone完成签到,获得积分10
2秒前
聪慧的怀绿完成签到,获得积分10
3秒前
XIY完成签到,获得积分10
3秒前
5秒前
5秒前
蓝天发布了新的文献求助30
5秒前
科研通AI6.2应助Xu采纳,获得10
6秒前
6秒前
大肥子完成签到,获得积分10
6秒前
望除完成签到,获得积分10
6秒前
JamesPei应助灿灿陈采纳,获得10
7秒前
阿赵发布了新的文献求助10
7秒前
molihuakai应助Sci采纳,获得10
8秒前
8秒前
不入当归完成签到,获得积分10
9秒前
9秒前
10秒前
11秒前
小蒋发布了新的文献求助10
13秒前
li完成签到,获得积分10
13秒前
科研通AI6.4应助霸气乐菱采纳,获得10
15秒前
陈仙仙发布了新的文献求助30
17秒前
ly2333完成签到,获得积分10
18秒前
20秒前
arniu2008应助痴情的诗槐采纳,获得20
21秒前
22秒前
22秒前
顾矜应助shuyingRen采纳,获得10
24秒前
大意的飞莲完成签到 ,获得积分10
24秒前
无情草莓发布了新的文献求助10
24秒前
25秒前
灿灿陈发布了新的文献求助10
25秒前
DODO完成签到,获得积分10
26秒前
jielo发布了新的文献求助10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
适配Micro-LED色转换的高兼容性量子点负性光刻胶制备与工艺研究 500
Direct and Iterative Linear System Solvers 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7313576
求助须知:如何正确求助?哪些是违规求助? 8930149
关于积分的说明 18927459
捐赠科研通 6973862
什么是DOI,文献DOI怎么找? 3213595
关于科研通互助平台的介绍 2381690
邀请新用户注册赠送积分活动 2191778